U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H19NO3S2
Molecular Weight 325.446
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZOFENOPRILAT

SMILES

C[C@H](CS)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC2=CC=CC=C2

InChI

InChIKey=UQWLOWFDKAFKAP-WXHSDQCUSA-N
InChI=1S/C15H19NO3S2/c1-10(9-20)14(17)16-8-12(7-13(16)15(18)19)21-11-5-3-2-4-6-11/h2-6,10,12-13,20H,7-9H2,1H3,(H,18,19)/t10-,12+,13+/m1/s1

HIDE SMILES / InChI

Molecular Formula C15H19NO3S2
Molecular Weight 325.446
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Zofenopril is an inhibitor of Angiotensin Converting Enzyme (ACE), which is approved in Europe for the treatment of hypertension and acute myocardial infarction.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
10.9 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZOPRANOL
Primary
ZOPRANOL
PubMed

PubMed

TitleDatePubMed
Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).
1989
Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension.
1989 Mar
Zofenopril after anterior myocardial infarction.
1995 Jun 22
Effect of Zofenopril on regeneration of sciatic nerve crush injury in a rat model.
2009 Jun 9
Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4).
2012
Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMILE-4.
2013
Cardioprotective role of zofenopril in patients with acute myocardial infarction: a pooled individual data analysis of four randomised, double-blind, controlled, prospective studies.
2015
Randomised comparison of zofenopril and ramipril plus acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a post hoc analysis of the SMILE-4 Study in patients according to levels of left ventricular ejection fraction at entry.
2015
Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial.
2015
Zofenopril Protects Against Myocardial Ischemia-Reperfusion Injury by Increasing Nitric Oxide and Hydrogen Sulfide Bioavailability.
2016 Jul 5
Efficacy of Zofenopril Compared With Placebo and Other Angiotensin-converting Enzyme Inhibitors in Patients With Acute Myocardial Infarction and Previous Cardiovascular Risk Factors: A Pooled Individual Data Analysis of 4 Randomized, Double-blind, Controlled, Prospective Studies.
2017 Jan
Patents

Sample Use Guides

In Vivo Use Guide
The usual effective dose in hypertension is 30 mg/day (in patients without volume or salt depletion) and the starting dose is 7.5 or 15 mg/day (in patients with volume or salt depletion). In acute myocardial infarction the treatment scheme is the following: 7.5 mg every 12 h (1st and 2nd day); 15 mg every 12 h (3rd and 4th day); 30 mg every 12 h (from 5th day).
Route of Administration: Oral
In Vitro Use Guide
Zofenopril (36 uM) significantly increased coronary flow after 5 min of incubation with isolated rat hearts.
Substance Class Chemical
Created
by admin
on Tue Oct 22 05:45:14 UTC 2019
Edited
by admin
on Tue Oct 22 05:45:14 UTC 2019
Record UNII
4G4WDK2YBS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZOFENOPRILAT
INN  
INN  
Official Name English
L-PROLINE, 1-(3-MERCAPTO-2-METHYL-1-OXOPROPYL)-4-(PHENYLTHIO)-, (1(R*),2ALPHA,4ALPHA)-
Systematic Name English
ZOFENOPRILAT [INN]
Common Name English
L-PROLINE, 1-(3-MERCAPTO-2-METHYL-1-OXOPROPYL)-4-(PHENYLTHIO)-, (1(R*),2.ALPHA.,4.ALPHA.)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C247
Created by admin on Tue Oct 22 05:45:14 UTC 2019 , Edited by admin on Tue Oct 22 05:45:14 UTC 2019
Code System Code Type Description
CAS
75176-37-3
Created by admin on Tue Oct 22 05:45:14 UTC 2019 , Edited by admin on Tue Oct 22 05:45:14 UTC 2019
PRIMARY
MESH
C065520
Created by admin on Tue Oct 22 05:45:14 UTC 2019 , Edited by admin on Tue Oct 22 05:45:14 UTC 2019
PRIMARY
IUPHAR
6463
Created by admin on Tue Oct 22 05:45:14 UTC 2019 , Edited by admin on Tue Oct 22 05:45:14 UTC 2019
PRIMARY
WIKIPEDIA
ZOFENOPRILAT
Created by admin on Tue Oct 22 05:45:14 UTC 2019 , Edited by admin on Tue Oct 22 05:45:14 UTC 2019
PRIMARY
PUBCHEM
3034048
Created by admin on Tue Oct 22 05:45:14 UTC 2019 , Edited by admin on Tue Oct 22 05:45:14 UTC 2019
PRIMARY
INN
6599
Created by admin on Tue Oct 22 05:45:14 UTC 2019 , Edited by admin on Tue Oct 22 05:45:14 UTC 2019
PRIMARY
EPA CompTox
75176-37-3
Created by admin on Tue Oct 22 05:45:14 UTC 2019 , Edited by admin on Tue Oct 22 05:45:14 UTC 2019
PRIMARY
EVMPD
SUB00171MIG
Created by admin on Tue Oct 22 05:45:14 UTC 2019 , Edited by admin on Tue Oct 22 05:45:14 UTC 2019
PRIMARY
NCI_THESAURUS
C95293
Created by admin on Tue Oct 22 05:45:14 UTC 2019 , Edited by admin on Tue Oct 22 05:45:14 UTC 2019
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
ACTIVE MOIETY